Pharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetes

@inproceedings{Liao2017PharmacogeneticsOD,
  title={Pharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetes},
  author={Wen-ling Liao and Wen-Jane Lee and Ching-Chu Chen and Chieh Hsiang Lu and Chien-Hsiun Chen and Yi-chun Chou and I-Te Lee and Wayne H-H Sheu and Jer-Yuarn Wu and Chi-fan Yang and Chung-Hsing Wang and Fuu-Jen Tsai},
  booktitle={Oncotarget},
  year={2017}
}
Dipeptidyl peptidase-4 (DPP-4) inhibitors are oral anti-hyperglycemic drugs enabling effective glycemic control in type 2 diabetes (T2D). Despite DPP-4 inhibitors' advantages, the patients' therapeutic response varies. In this retrospective cohort study, 171 Taiwanese patients with T2D were classified as sensitive or resistant to treatment based on the mean change in HbA1c levels. Using an assumption-free genome-wide association study, 45 single nucleotide polymorphisms (SNPs) involved in the… CONTINUE READING

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 47 REFERENCES

Similar Papers

Loading similar papers…